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ABSTRACT
We reported previously a model of polyglutamine repeat disorders with insertion of 146 CAG
repeats into the murine hypoxanthine phosphoribosyl transferase locus (Hprt(CAG)146; Ordway et
al. [1997] Cell 91:753–763), which does not normally contain polyglutamine repeats. These mice
develop an adult-onset neurologic phenotype of incoordination, involuntary limb clasping, sei-
zures, and premature death. Histologic analysis demonstrates widespread ubiquinated neuronal
intranuclear inclusions (NIIs). We now report characterization of the age of onset of behavioral
abnormalities, correlated with the time course of occurrence of NIIs in several brain regions, and
the occurrence of NIIs in non-neuronal tissues. Onset of behavioral abnormalities occurred at
approximately 22 weeks of age. There was variable time course of expression of NIIs in several
brain regions. Assessment of several non-neuronal tissues revealed nuclear inclusions in hepa-
tocytes and choroid plexus epithelium. -Aminobutyric acid (GABA)/benzodiazepine receptors,
dopamine D1-like and D2-like receptors, and type 2 vesicular monoamine transporter (VMAT2)
binding sites were assayed before and after the onset of behavioral abnormalities. GABA/
benzodiazepine receptors were unchanged either before or after the onset of behavioral abnor-
malities in any region analyzed, whereas striatal D1-like and D2-like receptors were diminished
after but not before the onset of symptoms. Dorsal striatal VMAT2 binding sites were decreased
before the onset of behavioral changes. Mitochondrial electron transport chain components were
assayed with histochemical methods before and after the onset of behavioral changes. There was
no change in behaviorally presymptomatic or symptomatic animals. Hprt(CAG)146 mice did not
exhibit increased susceptibility to the mitochondrial toxin 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine. Hprt(CAG)146 mice are a useful model for studying polyglutamine repeat
disorders. J. Comp. Neurol. 465:205–219, 2003. © 2003 Wiley-Liss, Inc.
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Nine human neurodegenerative diseases are caused by
expanded CAG-polyglutamine (polyQ) repeats within nine
unrelated genes. Huntington disease (HD; Huntington’s
Disease Collaborative Research Group, 1993), denta-
torubropallidal-luysian atrophy (DRPLA), spinobulbar
muscular atrophy (SMBA; Kennedy-Alter-Sung syn-
drome), and spinocerebellar ataxias 1, 2, 3 (synonymous
with Machado-Joseph disease [MJD]), 6, 7, and 17 com-
prise the identified polyQ family of diseases (Taylor et al.,
2002). Other than the CAG repeat sequences, these loci
exhibit little sequence similarity. The expanded polyQ
repeats may cause neurodegeneration by means of “gain of
function” mechanisms by imparting novel neurotoxic
properties. There are suggestions also of possible “loss of
function” effects (Ferrer et al., 2000; Dragatsis et al., 2000;
Zuccato et al., 2001). Common features of this disease
family include dominant inheritance, anticipation of age
of onset, length thresholds for the development of pathol-
ogy around 38–40 CAG repeats (except for SCA6; [Jen,
2003]), and with the exception of SBMA, where dorsal root
ganglia are affected, degeneration restricted to the central
nervous system. Each polyglutamine repeat disorder has a
unique regional pattern of neuropathology. Within af-
fected regions, there is often subpopulation-specific loss of
neurons (Iizuka and Hirayama, 1986; Gouw et al., 1994,
Takiyama et al., 1994; Robitaille et al., 1995; Holmberg et
al., 1998; Yang et al., 2000; Fujigasaki et al., 2001; Bazzett
and Albin, 2001; Pulst, 2003).
Polyglutamine repeat diseases share a common his-
topathologic hallmark; intraneuronal aggregates of pro-
teolytic fragments of the pathogenic protein containing
the polyQ domain (Davies et al., 1997; Paulson et al.,
1997; Becher et al., 1998). The inclusions are often
ubiquinated and contain other proteins. Aggregates occur
within the nucleus (neuronal intranuclear inclusions,
NIIs) and the cytoplasm. There is good evidence that in-
tranuclear localization of polyQ-containing fragments is a
key step in the pathogenesis of neurodegeneration, but the
specific pathogenic role of NIIs is unclear (Klement et al.,
1998; Saudou et al., 1998; Kim et al., 1999; Cummings et
al., 1999).
Ultrastructural evidence of NIIs in HD was published
approximately 30 years ago, but their significance was
unappreciated until their rediscovery in murine genetic
models of HD (Tellez-Nagel et al., 1974; Mangiarini et al.,
1996; Davies et al., 1997). The rediscovery of NIIs empha-
sizes the importance of murine genetic models. Transgenic
and knockin murine models of several CAG repeat disor-
ders have been created that reproduce several aspects of
the human diseases (Burright et al., 1995; Ikeda et al.,
1996; Mangiarini et al., 1996; Reddy et al., 1998; Hodgson
et al., 1999; Levine et al., 1999; Sato et al., 1999; Schilling
et al., 1999; Shelbourne et al., 1999; Huynh et al., 2000;
Wheeler et al., 2000; La Spada et al., 2001; Lin et al., 2001;
Katsuno et al., 2002; Watase et al., 2002; Yoo et al., 2003).
The common features of these diseases suggest common
mechanisms of pathology driven by the expanded CAG
repeats, modified possibly by expression patterns and sur-
rounding sequences of the affected proteins. This infer-
ence predicts that expanded CAG repeats would be neu-
rotoxic in any appropriately expressed “carrier” gene. We
evaluated this prediction by developing a mouse line with
146 CAG repeats in the hypoxanthine phosphoribosyl
transferase locus, (Hprt(CAG)146), a gene that does not
normally include CAG repeats. This line has adult-onset
neurologic abnormalities, shortened life span, and wide-
spread expression of NIIs, confirming the primary impor-
tance of the expanded CAG repeat domains (Ordway et al.,
1997). Hprt is inactivated in these animals. Because Hprt
inactivation in mice is devoid largely of major conse-
quences, these results are consistent with the gain of
function concept (Jinnah et al., 1991, 1992, 1994).
We report additional data on this line, including more
precise determination of the age of onset of the behavioral
changes, the time course of development of NIIs in mice
characterized for behavioral abnormalities, the pattern of
alterations in neurotransmitter markers, the integrity of
mitochondrial electron transport chain markers, and sus-




The Hprt(CAG)146 knockin mouse line generated by gene
targeting in mouse embryonic stem (ES) cells (Ordway et
al., 1997) was used in all experiments. These studies were
carried out on hemizygous males and homozygous females
derived from breeding of heterozygous females with hemi-
zygous males. Hprt is an X-linked locus and females ex-
press one copy of the locus due to X-inactivation. Offspring
from these matings were genotyped by polymerase chain
reaction using primers flanking the repeat region as de-
scribed previously (Ordway et al., 1997). Initial work in-
dicated no significant differences in the pathology of male
and female mutants. Control animals were similarly gene-
targeted mice with 70 CAG repeats inserted in the Hprt
locus (Hprt(CAG)70). These mice do not develop behavioral
changes or NIIs and have normal life spans (Ordway et al.,
1999).
Behavioral analysis
Twenty seven Hprt(CAG)146 mice, 15 to 24 weeks old,
were analyzed to more precisely define the age of onset of
behavioral abnormalities. Animals younger than 15 weeks
never showed behavioral abnormalities. Control animals
were 12 Hprt(CAG)70 mice, aged 24 to 64 weeks. Animals
were housed separately for behavioral analysis. Cages
were placed in a brightly lit laminar flow hood and cage
tops removed. Normal mice will actively move about the
cage under these conditions. Each mouse was scored as
active if it roamed from its initial position or reared within
30 seconds of cage lid removal. Mice were then held sus-
pended by the tail for 1 minute. Normal mice flail, extend
limbs, and attempt to escape by climbing onto the tester’s
finger. Clasping of the fore- or hindlimbs is abnormal and
was scored as present or absent. Mice able to climb onto
the tester’s finger within 1 minute were scored as escap-
ing; those unable to escape were scored as abnormal. For
rotarod analysis, mice were placed on a 4 cm diameter
rotarod turning at 2.5 rpm 30 cm above a padded cage
bottom (Ugo Basile, Comeria, Italy). Mice were scored as
falling or not falling within a 60-second trial. Animals
underwent 10 trials on 10 consecutive days. If a test was
abnormal on 20% of trials, that animal was scored as
abnormal on that test. If a seizure was witnessed during
any trials, that animal was scored as having epilepsy.
Animals were assigned a point for each abnormality on
each test—diminished spontaneous activity, clasping, in-
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ability to escape from suspension, falling from the rotarod
within 60 sec, and presence of epilepsy—for a cumulative
behavioral abnormality score with a possible total of 5
points. The higher the score, the greater number of
behavioral abnormalities. Statistical analysis was per-
formed between group behavioral abnormality scores
with the nonparametric Mann–Whitney U test using




Mice were deeply anesthetized by intraperitoneal injec-
tion of Avertin (Aldrich, 0.4 mg/g i.p.) and perfused
through the heart with approximately 100 ml of 0.1 M
phosphate buffer (PB, pH 7.4) followed by approximately
100 ml of 4% paraformaldehyde in PB. Organs were re-
moved, post-fixed overnight in 4% paraformaldehyde in
PB and cryoprotected in sucrose/PB (up to 20% sucrose).
Frozen brains were cut into 40-m sections in the hori-
zontal plane. Sections were sequentially collected in 1 in 5
series so that each group contained one section every 200
m throughout the brain. Heart, liver, lung, kidney,
spleen, testes, and skeletal muscle were processed simi-
larly. Tissue sections were stained with rabbit polyclonal
antiserum against ubiquitin (1:250 or 1:1,000 dilution;
Dako) overnight at 4°C. Hprt immunoreactivity was visu-
alized with a rabbit polyclonal antipeptide antisera di-
rected against amino acids 7-17 of Hprt. The antiserum
identified a single appropriate band on Western blots. For
immunohistochemistry, both 1:500 and 1:2,000 dilutions
were used and gave identical results. Primary antisera
were diluted in PB, 0.3% Triton X-100, and 1.5% blocking
serum. Processing was completed with the ABC method
using Vectastain Elite kits (Vector Laboratories, Te-
mecula, CA). Detection was performed by using a diami-
nobenzidine (DAB) substrate and NiCl2 according to the
manufacturer’s recommended protocol (Vector Laborato-
ries). Sections were dehydrated in graded alcohols and
xylenes and mounted on gelatin-coated slides, and cover-
slips were affixed with Permount (Fisher, Pittsburgh, PA).
Sections were viewed on a Nikon Eclipse E800 microscope.
Adjacent series of sections were stained with 0.5% cresyl
violet.
For quantification, ubiquitin-immunostained sections
were used. By approximately 30 weeks of age, NIIs were
found in virtually all regions examined. Regions were
selected for quantification on the basis of relevance to
human pathology (striatum, cerebellar cortex), early oc-
currence of NIIs (parabrachial nucleus), late occurrence of
NIIs (globus pallidus), and to provide a representative
sampling of other regions (frontal cortex, hippocampal
formation, superior colliculus). NIIs were visualized by
light microscopy at 800 and counted by using an ocular
grid. To provide approximate frequencies of NIIs, the
number of NIIs counted was divided by the number of
cresyl violet–stained neurons in fields from the same ar-
eas of adjacent cresyl violet–stained sections. Cresyl
violet–stained neurons were distinguished from glia by
characteristic nuclear and nucleolar morphology. At least
five fields were counted per brain region per brain. Brains
were scored as lacking NIIs only after thoroughly scan-
ning all sections within a group that included sections at
200-m intervals throughout the brain. Parallel confirma-
tory experiments were performed with an N-terminal
Hprt antiserum.
Receptor autoradiography
Hprt(CAG)146 and control mice of various ages were
killed by decapitation, and brains were extracted from the
cranial vault, coated with Shandon–Lipshaw embedding
matrix, and frozen in isopentane cooled by liquid N2.
Brains were stored at 70°C until time of sectioning.
Brains were warmed to 20°C, and 12- sections were cut
on a cryostat and thaw-mounted onto gelatin-coated slides
and stored at 70°C.
Receptor autoradiography was performed as described
previously (Richfield et al., 1989; Higgins and
Greenamyre, 1996; Suzuki et al., 2001). To label type 2
vesicular monoamine transporter (VMAT2) binding sites,
slides were prewashed for 5 minutes at room temperature
(RT) in KBS-ethylenediaminetetraacetic acid buffer (pH
8.0), then incubated with 10 nM [3H]methoxytetrabena-
zine (specific activity 82 Ci/mmol). Tetrabenazine (10 M)
was added to the ligand buffer to determine nonspecific
binding. After incubation, sections were rinsed twice for 2
minutes in cold assay buffer, dipped in cold distilled wa-
ter, and dried under cool air.
Assays for D1 and D2 dopamine receptors used a 25 mM
Tris buffer (pH 7.2) with 100 mM NaCl, 1 mM MgCl2, 1
M pargyline and 0.001% ascorbic acid. For D1 receptors,
slides were incubated with 0.55 nM [3H]SCH23390 (spe-
cific activity 89 Ci/mmol) for 2.5 hours. Nonspecific bind-
ing was determined in the presence of 1 M cis-
flupentixol. For D2 receptors, slides were incubated in
0.75 nM [3H]spiperone (specific activity 96 Ci/mmol) with
100 nM mianserin for 2.5 hours. Nonspecific binding was
defined in the presence of 50 M dopamine. After incuba-
tion, slides were rinsed in cold incubation buffer for 10
minutes, dipped in distilled water, and dried under cool
air. Slides for -aminobutyric acid (GABA)/benzodiazepine
receptor assays were prewashed for 30 minutes in cold
assay buffer (50 mM Tris-citrate buffer, pH 7.2), air-dried,
and incubated with 5 nM [3H]flunitrazepam (specific ac-
tivity 85 Ci/mmol) for 30 minutes at 4°C. Nonspecific
binding was determined in the presence of 2 M clonaz-
epam in the ligand buffer. Sections were rinsed twice for 5
minutes in cold buffer and dried under warm air. Binding
to complex I of the electron transport chain was examined
by using 5 nM [3H]dihydroxyrotenone (DHR; specific ac-
tivity 60 Ci/mmol) in 50 mM Tris-HCl buffer, 1% bovine
serum albumin (pH 7.6). Sections were incubated in li-
gand buffer for 2 hours at RT. Nonspecific binding was
assessed by using 10 M rotenone. Slides were rinsed in
RT incubation buffer for 1 hour, followed by two 5-minute
washes in 25 mM Tris-HCl (pH 7.6) and 15 seconds in
distilled water, then dried under a stream of warm air.
Tritium-labeled slides were apposed to tritium-sensitive
film (Hyperfilm 3H or BioMax, Amersham) with calibrated
radioactive standards and exposed for 2 to 5 weeks. Films
were developed and analyzed by using a computer-based
image analysis system (MCID, Imaging Research, St. Ca-
tharine’s, Ontario, Canada). Image density corresponding
to binding of tritiated ligand was converted to pmol/mg
protein using the calibrated standards. Specific binding
was determined by subtracting nonspecific from total
binding. Results were analyzed by using the VassarStats
program with a correlated t test.
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Histochemistry
For cytochrome oxidase histochemistry, slides were in-
cubated in 0.1 M HEPES buffer (pH 7.4) with 3.165 mM
nickel ammonium sulfate, 117 mM sucrose, 16.15 M
cytochrome C, and 2.778 mM DAB for 30–45 minutes at
37°C. The sections were rinsed twice, 10 minutes each, in
fresh HEPES buffer, dipped in distilled water, air-dried,
dehydrated, and cover-slipped. For succinate dehydroge-
nase histochemistry, slides were incubated in 60 mM
phosphate buffer (pH 7.0) with 0.04% nitro blue tetrazo-
lium and 50 mM succinate for 45 minutes at 37°C. The
sections were then soaked for 10 minutes in 4% parafor-
maldehyde in 50 mM Phosphate buffer (pH 7.0), rinsed in
distilled water, dehydrated, and cover-slipped. Sections
were analyzed by measuring optical density using a com-
puter assisted MCID image analysis system (Imaging Re-
search). Regional optical density was quantified using a
uniform gray scale under uniform illumination conditions.
Results were compared using a correlated t test with the
VassarStats program.
MPTP lesions
Mice of varying ages and genotype were treated with 0,
20, or 40 mg/kg MPTP injected intraperitoneally in four
divided doses given at 2-hour intervals. After 7 days, the
animals were killed by decapitation. Groups included both
male and female mice. Genders of mice were balanced
within almost all groups, and there was no effect of gender
on results. The forebrains were frozen and processed for
autoradiography as described above.
Image preparation
Photomicrographs were prepared by photographing im-
ages with an Olympus BX-51 microscope equipped with
SPOT-RT digital camera (Diagnostic Instruments, Ster-
ling Heights, MI). Autoradiographic and histochemical
images were captured with an MCID apparatus (Imaging
Research). Images were imported into Photoshop 5.5




Hprt(CAG)146 mice began to manifest significant behav-
ioral changes at approximately 22 weeks of age. To con-
firm this impression, Hprt(CAG)146 mice were divided into
two groups; 15 to 21 weeks old (n  15) and 22 to 24 weeks
old (n  11), and intergroup differences in cumulative
behavioral abnormality scores (summation of all individ-
ual behavioral tests scored as normal or abnormal; see
Materials and Methods section above) assessed with the
nonparametric Mann–Whitney U test (Fig. 1). For the 15-
to 21-week group, the mean rank was 8.7. For the 22- to
24-month group, mean rank was 20. This difference is
significant (P  0.0002; two-tailed test). The 22- to 24-
week group was compared also with a group of Hprt(CAG)70
control mice; 23 to 24 weeks old (n  6), 26 to 29 weeks old
(n  2), and 60 to 64 weeks old (n  4); total n  12. The
mean rank of Hprt(CAG)70 mice was 6.7. The mean rank of
the Hprt(CAG)146 mice was 17.8. This difference is signifi-
cant (P  0.0001, two-tailed test). The Hprt(CAG)146 mice
15 to 21 weeks old and the Hprt(CAG)70 mice did not differ
significantly in cumulative behavioral scores; both with
mean rank of 14 (P  0.984, two-tailed test). The normal
results in Hprt(CAG)70 mice and Hprt(CAG)146 mice 15 to 21
weeks old are consistent with our prior experience with
wild-type and Hprt knockout mice, where behavioral ab-
normalities on this battery of tests are seen only rarely,
even in older animals (Ordway et al., 1997, 1999).
Time course of occurrence of NIIs
NII occurrence was surveyed with ubiquitin immuno-
histochemistry in Hprt(CAG)146 mice 15 to 18 weeks old, 20
to 26 weeks old, 32 to 38 weeks old, and 40 to 46 weeks old
(n  3–4 for each group). Assessing NII occurrence in
older animals is difficult because of steeply rising mortal-
ity after 40 weeks. NII burden was assessed by estimating
the percentage of Nissl-stained neurons expressing NIIs.
No ubiquitin immunoreactive NIIs were found in the 15-
to 18-week age group (Table 1; Fig. 2). In older animals,
NIIs were detectable in varying numbers in all regions
surveyed. In the 20- to 26-month age group, NIIs were
present in a substantial percentage of neurons in the
parabrachial nucleus and frontal cortex, i.e., 58% and
37%, respectively. Moderate percentages of NIIs (20%
and 10%) were present in cerebellar Purkinje cells, sub-
stantia nigra pars compacta neurons, superior colliculus
neurons, and inferior colliculus neurons. Less than 10% of
neurons in the hippocampal formation, striatum, globus
pallidus, or substantia nigra pars reticulata expressed
NIIs. In the 32- to 38-week age group, the regional distri-
bution and percentage of NIIs was similar to that found in
the 20- to 26-week age group with the possible exception of
parabrachial neurons where the percentage of NII-
containing neurons rose to 72%. In the 40- to 46-week age
group, all regions exhibited abundant NIIs. Percentage of
NIIs rose to 85% in the parabrachial nucleus and exceeded
60% in the frontal cortex, substantia nigra pars compacta,
cerebellar Purkinje cells, and hippocampal formation. Per-
centage of NIIs exceeded 50% in striatal neurons, superior
collicular neurons, and inferior collicular neurons. Even in
regions with the lowest percentages of NIIs, the substan-
tia nigra pars reticulata and the globus pallidus, percent-
age of neurons expressing NIIs was substantial, approxi-
mating 30%. Many regions displayed marked increases in
Fig. 1. Mean behavioral scores for Hprt(CAG)146 mice, 15–21 weeks
old, compared with Hprt(CAG)146, 22–24 weeks old, and Hprt(CAG)70
control mice. The 22- to 24-week age group has higher mean behav-
ioral scores than younger or control mice.
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the percentage of neurons containing NIIs in the interval
between the 32- to 38-week and 40- to46-week age groups.
In the frontal cortex, cerebellar Purkinje cells, globus pal-
lidus and substantia nigra pars compacta, there was a
two- to threefold increase the percentage of neurons con-
taining NIIs. In the remaining regions, the magnitude of
the increase was greater, approximately 5- to 10-fold. Sim-
ilar results were found with anti-Hprt antisera (Fig. 3).
NIIs in non–central nervous system tissue
Non–central nervous system tissues were studied in
two mutants, 30 and 46 weeks of age, and two wild-type
mice. NIIs were found in hepatocytes but not in heart,
lung, kidney, spleen, testes, or muscle (Fig. 4). NIIs were
seen also in choroid plexus epithelium (Fig. 4).
Receptor binding studies
GABA/benzodiazepine receptor, D1-like receptor, D2-
like receptor, and VMAT2 binding sites were assessed
before and after the onset of behavioral abnormalities in
Hprt(CAG)146 mice. Animals were assessed at approxi-
mately 16 weeks (n  4) and 45 weeks of age (n  7). These
results were compared with results from older (approxi-
mately 55 week) Hprt(CAG)70 mice as described in the
Fig. 2. Ubiquitin-immunoreactive neuronal intranuclear inclusions. Regions are cerebral cortex
(A–C), striatum (D–F), and parabrachial nucleus (G–I) at 15 weeks (A,D,G), 26 weeks (B,E,H), and 40
weeks (C,F,I). Arrows mark representative inclusions. Scale bar  75 m in I (applies to A–I).























15–18 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–26 57.8 36.6 18.0 17.1 16.4 16.3 7.5 4.7 4.5 3.8
32–38 72.0 22.7 23.3 20.9 11.7 7.5 10.0 7.8 4.8 7.2
40–46 84.6 63.4 64.9 65.6 50.5 58.7 65.9 31.9 56.6 27.5
1NIIs were identified with ubiquitin immunohistochemistry. Neurons were counted in parabrachial nuclei (PN), frontal cortex (CTX), cerebellar Purkinje cells (PRK), substantia
nigra pars compacta (SNc), superior colliculus (SC), inferior colliculus (IC), hippocampus (HIP) substantia nigra pars reticulata (SNr), striatum (STR), and globus pallidus (GP).
NII-positive neurons were counted manually using an eyepiece graticule in randomly selected fields. Total Nissl-stained neurons were counted in the same fields, and results are
expressed as percentage of total neurons per field. N  3–4 per group.
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Material and Methods section. Additional controls in-
cluded younger (16 week; n  4), middle aged (30 week;
n  4), and older (51 week; n  4) wild-type mice with
intact Hprt and older Hprt(CAG)39 mice (51 week; n  2).
Results from these controls were virtually identical to
results obtained from Hprt(CAG)70 mice (data not shown),
and Hprt(CAG)70 mice are believed to be the best control
group for Hprt(CAG)146 mice. At 16 weeks and 45 weeks,
there were not changes in GABA/BDZ binding sites in any
region (Table 2; Fig. 5). D1-like receptor and D2-like re-
ceptor binding sites were significantly reduced in the stri-
atal complex (striatum proper, nucleus accumbens, olfac-
tory tubercle) of older (45 week) but not younger (16 week)
Hprt(CAG)146 mice (Table 3; Fig. 5). In the substantia
nigra, D1-like receptor binding sites were reduced simi-
larly in older Hprt(CAG)146 mice. In the nigra, the great
majority of D1-like receptor binding sites are on striatoni-
gral terminals, and this finding is likely to reflect either
reduced synthesis of D1-like receptors by striatal projec-
tion neurons or loss of striatal terminals within the sub-
stantia nigra. There was a trend toward increased sub-
stantia nigra D2-like receptor binding. Nigral D2-like
receptors are expressed by substantia nigra dopaminergic
neurons, and this increase could represent a concentrative
effect of loss of surrounding neuropil due to degeneration
of afferent striatal projection neuron terminals. VMAT2
binding, a measure of striatal dopaminergic terminals,
was markedly reduced in the striatal complex and sub-
stantia nigra of older Hprt(CAG)146 mice (Table 3; Fig. 5).
In the younger Hprt(CAG)146 mice, VMAT2 binding was
reduced in the striatum proper, and there was a trend
toward reduced VMAT2 binding in the nucleus accum-
bens, olfactory tubercle, and substantia nigra. Alterations
in VMAT2 binding were the only changes we detected
before the onset of behavioral changes or NII formation.
Striatal VMAT2 binding is usually interpreted as a func-
tion of striatal dopamine terminal integrity but altered
expression of VMAT2 is another possible explanation for
this finding.
Mitochondrial electron transport chain
activities
Complex I expression was assessed with [3H]DHR bind-
ing, whereas Complex II/III and Complex IV activities
Fig. 3. Hprt-immunoreactive neuronal intranuclear inclusions. Regions are cerebral cortex
(A–C), striatum (D–F), and parabrachial nucleus (G–I) at 15 weeks (A,D,G), 26 weeks (B,E,H), and 40
weeks (C,F,I). Arrows mark representative inclusions. Scale bar  75 m in I (applies to A–I).
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were assessed histochemically with succinate dehydroge-
nase (SDH) and cytochrome oxidase (CyOx) histochemistry,
respectively. [3H]DHR binding was measured in young
(16 week; n  4) and older (45 week; n  7) Hprt(CAG)146
mice. Controls were older (56 week; n  12) Hprt(CAG)70
mice. In all regions evaluated of older Hprt(CAG)146 mice,
there was a nonsignificant trend toward increases in
[3H]DHR binding compared with Hprt(CAG)70 mice (Table
4; Fig. 6). Younger Hprt(CAG)146 mice were indistinguish-
able from Hprt(CAG)70 mice. Similar results were obtained
with SDH and CyOx histochemistry (Table 4; Fig. 6). In all
brain regions examined in all age groups, there was no
difference in SDH or CyOx activity between Hprt(CAG)146
and Hprt(CAG)70 mice.
Susceptibility to MPTP
To assess the vulnerability of Hprt(CAG)146 mice to mi-
tochondrial impairment, we chose the neurotoxin MPTP.
MPTP is a protoxin selective for dopaminergic neurons.
MPTP is converted to MPP with the latter species selec-
tively accumulated in dopaminergic neurons where it in-
hibits Complex I. We chose this approach because of ease
TABLE 2. [3H]Flunitrazepam Binding1
Genotype n
Age in weeks
(	SEM) Striatum nAccumbens SNc TempCx FrPar Cx Hippo MlCblm GclCblm
HprtQ146 7 44.94 (1.0) 102.57 (18.46) 123.01 (10.22) 90.50 (9.34) 119.21 (5.16) 105.12 (5.42) 99.20 (11.49) 101.85 (16.54) 130.15 (35.35)
HprtQ146 4 16.5 (0.5) 94.48 (13.92) 108.88 (11.19) 95.18 (6.73) 98.11 (4.37) 83.50 (6.73) 91.55 (8.86) 95.65 (10.46) 112.98 (17.75)
HprtQ70 7 55.0 (1.5) 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
1nAccumbens, nucleus accumbens; SNc, substantia nigra, pars compacta; TempCx, temporal cortex; FrPar Cx, frontoparietal cortex; Hippo, hippocampus; MlCblm, molecular layer
of the cerebellar cortex; GclCblm, granular cell layer of the cerebellar cortex. Data are percentage of regional specific binding of [3H]flunitrazepam (	 SEM) relative to
[3H]flunitrazepam specific binding in aged Q70 animals. Specific binding determined by receptor autoradiography with conversion of film optical density to bound radioactivity
using coexposed radioactive standards to generate a standard curve relating optical density to radioactivity. None of the comparisons reached significance at P  0.05.
Fig. 4. Neuronal intranuclear inclusions in non–central nervous system tissues. Ubiquitin-
immunoreactivity in choroid plexus epithelium and liver of 30-week-old wild-type mouse (A,C) and
46-week-old Hprt(CAG)146 mouse (B,D). Arrows mark representative inclusions. Scale bar  75 m in D
(applies to A–D).
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of MPTP administration and ease of measurement of stri-
atal dopamine terminal density with the VMAT2 ligand
[3H]MTBZ. Expression of NIIs within substantia nigra
pars compacta neurons suggested that these neurons
might be more vulnerable to mitochondrial impairment
(Ordway et al., 1997). Hprt(CAG)146 mice at varying ages
(12–22 weeks, n  3–5; 27–32 weeks, n  5; 42–55 weeks,
n  5–6) were evaluated after receiving 0 mg/kg, 20 mg/
kg, and 40 mg/kg of MPTP as described in the Materials
and Methods section. The control animals were
Hprt(CAG)70 mice. As described above, there was a decline
in VMAT2 binding in the vehicle-treated Hprt(CAG)146
TABLE 3. Striatal–Nigral Dopamine Receptors and Terminals1
Genotype n
Age in weeks
(	SEM) Striatum nAccumbens OT SN
D1 receptors
HprtQ146 7 44.9 (1.0) 63.05 (6.16) 66.90 (4.43) 52.80 (4.82) 73.93 (8.00)
HprtQ146 4 16.5 (0.5) 96.40 (8.07) 91.11 (14.61) 82.56 (13.48) 77.94 (9.97)
HprtQ70 8 55.1 (1.28) 100.00 100.00 100.00 100.00
D2 receptors
HprtQ146 7 44.9 (1.0) 52.00 (4.56) 61.16 (4.87) 61.03 (5.77) 178.02 (64.19)
HprtQ146 4 16.5 (0.5) 94.65 (4.05) 95.718 (7.12) 81.47 (8.43) 85.78 (28.79)
HprtQ70 7 54.6 (1.3) 100.00 100.00 100.00 100.00
Dopamine terminals
HprtQ146 7 44.9 (1.0) 30.92 (8.01) 37.81 (8.12) 38.83 (8.63) 58.11 (11.56)
HprtQ146 4 16.5 (0.5) 57.38 (7.11) 75.61 (8.68) 84.82 (6.75) 77.84 (9.46)
HprtQ70 8 55.4 (1.3) 100.00 100.00 100.00 100.00
1nAccumbens, nucleus accumbens; OT, olfactory tubercule; SN, substantia nigra. Data are percentage of specific binding of [3H]SCH23390 for D1 receptors, [3H]spiperone for D2
receptors, [3H]methoxytetrabenazine for dopamine terminals (	 SEM) relative to specific ligand binding in aged Q70 animals. Specific binding determined by receptor
autoradiography with conversion of film optical density to bound radioactivity using coexposed radioactive standards to generate a standard curve relating optical density to
radioactivity. Bold values are significantly different from control values (P  0.05).
Fig. 5. Autoradiographs of type 2 vesicular monoamine trans-
porter (VMAT2) expression (a–c), D1 receptor expression (d–f), D2
receptor expression (g–i), and benzodiazepine/GABA-A receptor ex-
pression (j–l). Columns are 16-week-old Hprt(CAG)146 mice (a,d,g,j),
55-week-old Hprt(CAG)70 control mice (b,e,h,k), and 45-week-old
Hprt(CAG)146 mice (c,f,i,l). Striatal VMAT2 expression is reduced in
both young and older Hprt(CAG)146 mice. Striatal D1 receptor and D2
receptor expression are reduced in older Hprt(CAG)146 only.
Benzodiazepine/GABA-A receptor expression is unchanged in young
and old Hprt(CAG)146. Scale bar  5 mm in i (applies to a–i).
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mice compared with Hprt(CAG)70 mice. In contrast to the
results described above, differences between Hprt(CAG)70
and Hprt(CAG)146 mice were not seen in the youngest mice.
This finding is probably because this experiment included
some younger animals (12 weeks) than the experiments
described above (16 weeks). A total of 40 mg/kg MPTP
treatment reduced striatal VMAT2 binding sites in both
Hprt(CAG)146 and Hprt(CAG)70 mice at young and older ages
(Table 5; Fig. 7). The magnitude of the reduction in stri-
atal VMAT2 binding, as measured by percentage loss of
striatal VMAT2 binding compared with vehicle-treated
controls was actually greater in Hprt(CAG)70 mice than in
Hprt(CAG)146 mice (Table 5). In the oldest Hprt(CAG)70
mice, the effect of MPTP appeared to be greater than in
the youngest Hprt(CAG)70 mice. Although the vehicle-
treated controls had very similar levels of striatal VMAT2
binding, the percentage decline in striatal VMAT2 binding
after 40 mg/kg treatment was approximately twice as
great in the older animals. Similarly, although the 20
mg/kg dose produced no effect in younger Hprt(CAG)70
mice, there was an effect in the oldest Hprt(CAG)70 mice.
There is no differential effect of MPTP between
Hprt(CAG)146 and Hprt(CAG)70 mice, and there may be an
age enhanced susceptibility to MPTP in Hprt(CAG)70 mice.
Fig. 6. Electron transport chain measures in young (16 weeks,
a,d,g), aged (45 weeks, c,f,i) Hprt(CAG)146, and aged (45 week, b,e,h)
Hprt(CAG)70 control mice. Top row (a–c) is [3H]dihydrorotenone bind-
ing to complex I; second row (d–f) is succinate dehydrogenase activity,
and third row (g–i) is cytochrome oxidase activity. There is no differ-
ence between young Hprt(CAG)146 mice, aged Hprt(CAG)146 mice, and
aged control Hprt(CAG)70 mice. Scale bar  3 mm in i (applies to d–i);
4 mm in a–c.






HprtQ146 12–22 3–4 Striatum 103.462 0.252 0.435
HprtQ146 12–22 3–4 Sensorimotor cortex 129.392 0.235 0.530
HprtQ146 45 5–7 Striatum 134.812 0.268 0.436
HprtQ146 45 5–7 Sensorimotor cortex 123.502 0.263 0.610
HprtQ70 12–22 4–12 Striatum 100 0.321 0.423
HprtQ70 12–22 4–12 Sensorimotor cortex 100 0.281 0.529
HprtQ70 45 4–12 Striatum 100 0.287 0.444
HprtQ70 45 4–12 Sensorimotor cortex 100 0.257 0.549
1DHR, [3H]dihydrotenone binding; SDH, succinate dehydrogenase activity; CyOx, cytochrome oxidase activity. DHR binding is expressed as percentage of specific [3H]Dihydro-
tenone binding in HprtQ70 animals. SDH and CyOx activity measured as optical density of regions on fresh frozen cryostat prepared sections with standard histochemical methods
(see Materials and Methods section for details). No difference found between young or aged HprtQ146 or HprtQ70 mice. Similar results found in other brain regions (data not
shown) and also after regional optical density was normalized to whole brain optical density. Hprt, hypoxanthine phosphoribosyl transferase locus.
2DHR binding is specific binding of [3H]dihydrotenone determined by receptor autoradiography with conversion of film optical density to bound radioactivity using coexposed
radioactive standards to generate a standard curve relating optical density to radioactivity.
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DISCUSSION
Age of onset of behavioral abnormalities
We showed previously that Hprt(CAG)146 mice develop
adult-onset behavioral abnormalities, have premature
mortality, and exhibit abundant NIIs (Ordway et al.,
1997). Consistent with prior data, cumulative behavioral
scores became abnormal at approximately 22 weeks of
age. Repeat length is an important determinant of age of
onset and penetrance (Stine et al., 1993; Rubinsztein et
al., 1996). Over some threshold, repeat number correlates
inversely with age of onset of clinical disease (Hunting-
ton’s Disease Collaborative Research Group, 1993; Rubin-
sztein et al., 1997) and accounts for approximately 50% of
the variance in age of onset. In murine genetic models,
repeat number and the amount of gene product have in-
fluenced age of onset (reviewed in Zoghbi and Botas,
2002). In transgenic models, expanded CAG repeats in
truncated constructs and/or high expression of transgenes
are required to produce a phenotype. With knockin models
of HD and SCA1, significant behavioral phenotypes de-
velop only with CAG repeat expansions greater than those
found typically in human patients (Lin et al., 2001; Me-
nalled et al., 2002; Wheeler et al., 2002; Zoghbi and Botas,
2002; Watase et al., 2002). The relatively short life span of
mice may limit the opportunity to observe the effects of
repeat lengths that are pathogenic in humans. Existing
methods of behavioral evaluation may also be insuffi-
ciently robust to detect earlier changes.
The amount of mutant protein produced may also affect
age of onset. The R6 transgenic HD lines developed by
Bates’ group vary in repeat number and levels of protein
expression (Mangiarini et al., 1996). Lines with higher
repeat numbers and higher levels of protein expression
have a more aggressive phenotype. In a transgenic yeast
artificial chromosome (YAC) model of HD with 43 repeats,
abnormalities are found only with supranormal expres-
sion levels of the mutant protein (Reddy et al., 1998). In
our knockin model of HD, mutant homozygous animals
develop behavioral abnormalities at an earlier age than
heterozygous animals (Lin et al., 2001). Similar effects of
homozygosity are found in a knockin model of SCA7 (Yoo
et al., 2003). Homozygous HD mutation carriers were re-
ported originally to have clinical disease indistinguishable
from heterozygotes, but recent data indicates that HD
homozygotes have a more aggressive clinical course than
heterozygotes (Wexler et al., 1987; Squitieri et al., 2003).
Earlier age of onset is reported in SCA3/MJD and DRPLA
homozygotes (Sato et al., 1995; Sobue et al., 1996).









MPTP 0 100.2 (3) 60.8 (5) 73.1 (5)
MPTP 20 115.0 (3) 61.9 (5) 54.5 (5)
MPTP 40 66.5 (5) 34.1 (5) 40.6 (6)
Q70, Q70/70
MPTP 0 96.7 (5) 74.4 (1) 100.0 (4)
MPTP 20 111.3 (5) 90.0 (1) 66.2 (5)
MPTP 40 78.8 (5) 33.5 (1) 41.9 (4)
Q39, Q39/39
MPTP 0 97.3 (2) 90.7 (2) 155.8 (2)
MPTP 20 112.6 (2) 89.0 (2) 98.0 (2)
MPTP 40 86.1 (2) 42.0 (2) 56.5 (1)
1MPTP 0  vehicle administered, MPTP 20  20 mg/kg MPTP, MPTP 40  40 mg/kg
MPTP. [3H]MTBZ binding to dorsal striatal dopamine terminals determined by recep-
tor autoradiography with conversion of film optical density to bound radioactivity using
coexposed radioactive standards to generate a standard curve relating optical density
to radioactivity. Values expressed as percentage of striatal specific [3H]MTBZ binding
in Q39 and Q146 relative to specific [3H]MTBZ binding in old Q70 MPTP 0 animals.
Numbers in parentheses after percent values are the number of each group. There is no
difference in the effects of MPTP on [3H]MTBZ binding between Q146, Q70, and Q39
animals. MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Fig. 7. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) intoxication on Hprt(CAG)146 and Hprt(CAG)70 control mice of
different ages. Amounts administered are 0 mg/kg MPTP(a–d), 20
mg/kg MPTP (e–h), 40 mg/kg (i–l). First column (a,e,i) is 13-week
Hprt(CAG)70 mouse, second column (b,f,j) is 16-week Hprt(CAG)146
mouse, third column (c,g,k) is 45-week Hprt(CAG)70 mouse, fourth
column (d,h,l) is 45-week Hprt(CAG)146 mouse. There is no difference in
MPTP effects at any age or dose of MPTP. Scale bar  1.5 mm in l
(applies to a–l).
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Time course of NII accumulation
The role of NIIs in neurodegeneration is controversial.
By analogy with other forms of insoluble protein pathol-
ogy, e.g., Lewy bodies and amyloid plaques, NIIs and
cytoplasmic inclusions are suggested to be proximate
causes of neurodegeneration in CAG repeat disorders (Da-
vies et al., 1997; Ross, 1997, 2002; Scherzinger et al., 1997;
Becher et al., 1998; Sisodia, 1998; Trojanowski and Lee,
2000). Alternative interpretations of the role of NIIs are
that they are epiphenomena or that they could be protec-
tive (Ordway et al., 1997; Sisodia, 1998; Ross, 2002; Zog-
bhi and Botas, 2002).
NIIs were first visualized at approximately the same
age as the development of behavioral abnormalities. In
almost all regions studied, there was a marked increase in
the percentage of neurons expressing NIIs in the 40 to 46
week age group, paralleling the ages at which mortality
accelerates. This type of analysis cannot, however, estab-
lish causal relations between NIIs and behavioral abnor-
malities. We relied on ubiquitin immunohistochemistry to
quantify the presence of NIIs. Aggregation of polyglu-
tamine repeat-containing protein fragments may occur
earlier than easily demonstrable ubiquination. In HD
knockin mice, nuclear localization of huntingtin is an
early event and emergence of huntingtin-immunoreactive
NIIs precedes the development of ubiquitin-
immunoreactive NIIs (Wheeler et al., 2000; Tallaksen-
Greene et al., unpublished data). With anti-Hprt antisera,
we found a similar time course for NII emergence but our
reliance on ubiquitin immunohistochemistry for quantifi-
cation may underestimate the age of occurrence of NIIs
and the apparent correlation with behavioral abnormali-
ties may be spurious.
We found one region where evidence of neuronal dys-
function is dissociated from NII occurrence, the substantia
nigra pars compacta (SNpc). Dorsal striatal [3H]MTBZ
binding was decreased before NII occurrence in the SNpc.
[3H]MTBZ binding is an excellent marker of nigrostriatal
dopaminergic afferents (Vander Borght et al., 1995a, b).
Diminished [3H]MTBZ binding is due to either loss of
nigrostriatal dopaminergic afferents or relative down-
regulation of VMAT2 expression. Decreased striatal
[3H]MTBZ binding is a likely marker of neuronal dysfunc-
tion. Dissociation of NII expression from [3H]MTBZ bind-
ing changes argues against a primary pathogenic role for
NIIs in neurodegeneration.
In vitro and in vivo experiments dissociated the toxic
effects of expanded CAG repeat-containing intranuclear
fragments from NII formation (Saudou et al., 1998; Kle-
ment et al., 1998; Kim et al., 1999; Cummings et al., 1999;
Simeoni et al., 2000; Mastroberardino et al., 2002; Me-
nalled et el., 2002; Watase et al., 2002). In HD, there is not
a good correlation between striatal neuron subpopulation
expression of NIIs and the pattern of striatal neuron sub-
population degeneration (DiFiglia et al., 1997; Kuemmerle
et al., 1999). In SCA2, NIIs are expressed sparsely and
without good correlation with the pattern of neurodegen-
eration (Huynh et al., 2000). NIIs are probably not key
mediators of pathogenesis in polyglutamine repeat disor-
ders. NIIs could play a protective role by acting as a “sink”
for toxic expanded CAG repeat-containing proteolytic
fragments, and neurons able to form NIIs may be rela-
tively protected against the effects of expanded CAG re-
peats. Oligomerization of polyglutamine-containing frag-
ments, however, may be a key step in pathogenesis.
Disruption of oligomerization with the azo-dye Congo Red,
extends life span and reduces NII burden in R6/2 mice
(Sanchez et al., 2003). The role of NIIs could be multifac-
torial. In our data set, abundant NIIs were found in all
regions examined around the period when mortality rates
accelerated. NIIs may act as a protective sink in the early
stages of neuronal injury but assume a pathogenic role
later in the course of the disease.
Nuclear inclusions in non-neuronal tissues
We found nuclear inclusions in two non-neuronal cell
populations: hepatocytes and choroid plexus epithelium.
The relative lack of nuclear inclusions in non-neuronal
cells is interesting in view of the widespread expression of
Hprt. In R6/2 mice, which have diabetes, nuclear inclu-
sions have been found in pancreatic islet cells, skeletal
and cardiac muscle fibers, adrenal cortical cells, and my-
enteric plexus neurons (Hurlbert et al., 1999; Sathasivam
et al., 1999). It is unknown why NIIs are expressed pref-
erentially in neurons and why neurons are particularly
susceptible to the toxic effects of polyglutamine expan-
sions. Neurons are unusually long lived postmitotic cells
with an essentially zero rate of turnover in almost all
brain regions. Even low rates of cell turnover might purge
cells accumulating toxic polyglutamine-containing frag-
ments. Some mitotically active cell populations express
NIIs in R6/2 mice, and we did find nuclear inclusions in
hepatocytes, a renewable cell type. Factors governing the
expression of NIIs are likely to be complex, possibly in-
cluding cell-specific differences in cell life span and me-
tabolism of expanded polyglutamine-containing proteins.
Neurotransmitter marker changes and
transcriptional dysregulation
We found differential effects on neurotransmitter mark-
ers in Hprt(CAG)146 mice. In both young and older
Hprt(CAG)146 mice, there was no effect on expression of
GABA/benzodiazepine receptor binding sites. Striatal D1-
like and D2-like receptor binding site expression was di-
minished in older animals. Dorsal striatal VMAT2 binding
was diminished significantly before the development of
behavioral abnormalities and the occurrence of NIIs. The
normal expression of GABA/benzodiazepine receptor bind-
ing sites argues against nonspecific loss of neurotransmit-
ter marker binding sites due to neurodegeneration or non-
specific neuronal dysfunction. A similar result was
described in the R6/2 model of HD (Cha et al., 1998;
Reynolds et al., 1999). Of interest, in this line, there is a
similar decline in striatal dopamine terminal markers
when markers of intrinsic striatal neurons are preserved
(Reynolds et al., 1999; Hickey et al., 2002). A likely expla-
nation for this pattern of findings is selective loss of spe-
cific neurotransmitter markers due to transcriptional dys-
regulation (Luthi-Carter et al., 2000).
Considerable evidence indicates that transcriptional
dysregulation is not merely an epiphenomenon but central
to the pathogenesis of neurodegenerative polyglutamine
repeat disorders (Perutz et al., 1994; Boutell et al., 1999;
Lin et al., 2000; Luthi-Carter et al., 2000; McCampbell et
al., 2000, 2001; Holbert et al., 2001; Nucifora et al., 2001;
Steffan et al., 2000, 2001; Chai et al., 2001, 2002; Zhang et
al., 2002; Dunah et al., 2002; Katsuno et al., 2002;
Takeyama et al., 2002; Kegel et al., 2002). Evidence from
in vitro models and genetic models indicates that nuclear
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localization of expanded polyglutamine-containing
polypeptides, possibly in the form of caspase-produced
fragments, is a crucial step in pathogenesis (Goldberg et
al., 1996; Wellington et al., 1998, 2002; Li et al., 2000; Kim
et al., 2001). For a dissenting view, however, see Dyer and
McMurray (2001). Expanded polyglutamine-containing
polypeptides may aggregate with and sequester proteins
involved in transcription (Boutell et al., 1999; McCamp-
bell et al., 2000, 2001; Holbert et al., 2001; Nucifora et al.,
2001; Steffan et al., 2000; Chai et al., 2001, 2002; Zhang et
al., 2002; Dunah et al., 2002; Kegel et al., 2002). Evidence
from both human postmortem tissue and murine genetic
models of HD, SCA1, and DRPLA indicates altered tran-
scription in these diseases. Overexpression of sequestered
transcriptionally active proteins reverses some of the ef-
fects of mutant huntingtin and atrophin in some model
systems (Shimohata et al., 2000; Nucifora et al., 2001;
Dunah et al., 2002).
Transcriptional dysregulation is a plausible mechanism
for explaining the regional and subregional specificity of
neurodegeneration characteristic of polyglutamine dis-
eases. Different populations of neurons express different
complements of proteins active in transcription. Differen-
tial affinity of these proteins for the different expanded
polyglutamine-containing protein fragments could explain
differential regional and subregional neurodegeneration.
This model is supported by results from a murine trans-
genic model of SCA7 where specific interference with the
homeobox protein CRX is suggested to underlie retinal
degeneration (La Spada et al., 2001). On the other hand,
recent data from a knockin model of SCA7 contradicts this
result (Yoo et al., 2003).
Mitochondrial dysfunction
One creditable proximate cause of neurodegeneration in
HD is excitotoxic injury. Acute N-methyl-D-aspartate
(NMDA) receptor agonist striatal excitotoxic lesions are
remarkable mimics of HD striatal pathology (Bazzett and
Albin, 2001). The most popular version of the excitotoxic
hypothesis suggests that mitochondrial dysfunction in-
creases neuronal susceptibility to NMDA receptor-
mediated excitotoxic injury, so-called indirect excitotoxic-
ity. Compounds that inhibit electron transport chain
activity cause striatal lesions with many features of HD
striatal pathology (Beal et al., 1993a, b; Greene and
Greenamyre, 1995; Bazzett et al., 1995). Several in vitro
and in vivo studies describe mitochondrial dysfunction in
HD or murine genetic models of HD (Jenkins et al., 1993;
Browne et al., 1997; Sawa et al., 1999, Tabrizi et al., 2000;
Panov et al., 2002). Guidetti et al. (2001), however, did not
find evidence of mitochondrial dysfunction in early post-
mortem HD material. The excitotoxic hypothesis predicts
that murine genetic models of HD should exhibit in-
creased susceptibility to mitochondrial toxins and/or
NMDA agonists. Conflicting data exist on this point (Bog-
danov et al., 1998; Hansson et al., 1999, 2001a, b; Levine
et al., 1999; Zeron et al., 2002). A large clinical trial based
on the indirect excitotoxicity hypothesis evaluated coen-
zyme Q10 (ubiquinone) as a mitochondrial function
booster and the NMDA receptor antagonist remacemide
(Huntington Study Group, 2001). There was no significant
effect of either compound or the combination, although
positive effects were seen in the R6/2 mouse model (Fer-
rante et al., 2002).
Our data do not support the notion of mitochondrial
dysfunction or increased susceptibility to mitochondrial
toxins. The indirect excitotoxic hypothesis is plausible, but
more evidence will be required to demonstrate its rele-
vance to polyglutamine diseases.
Knockin vs. transgenic models
A theoretical advantage of this model and other
“knockin” murine genetic models is that the expanded
CAG repeat sequences are expressed in the context of
their normal patterns of expression and regulatory genetic
elements. Transgenic murine models can have multiple
copies of transgenes, abnormal expression of polyglu-
tamine repeat-containing proteins, and transgene expres-
sion is not regulated by sequences that normally control
the pattern and level of expression. Transgenic models
provide considerable insight into the general processes
causing neurodegeneration but may not be close mimics of
specific human CAG repeat disorders. Knockin models of
HD, SCA1, and SCA7 exhibit somewhat different pheno-
types than seen in transgenic lines (Burright et al., 1995;
Mangiarini et al., 1996; La Spada et al., 2001; Lin et al.,
2001; Watase et al., 2002; Wheeler et al., 2002; Yoo et al.,
2003). Whereas knockin lines require very long repeat
numbers to produce a phenotype and the phenotype may
be less aggressive than seen in transgenic lines, the pat-
terns of pathology in knockin lines seem more similar to
the human diseases. Important factors influencing pheno-
type in murine genetic models of HD are the number of
repeats and the level of expression of mutant protein (see
discussion above; Zoghbi and Botas, 2002). Knockin lines
may have the virtue of disentangling the roles of repeat
number and level of protein expression. In knockin lines,
levels of expression are comparable from line to line and
differences in phenotype can be attributed to differences
in repeat number.
If transcriptional dysregulation is at the heart of patho-
genesis in polyglutamine disorders, then transgenic mod-
els with heightened levels of protein expression and non-
physiological distributions of gene expression may give
misleading impressions of key factors in the pathogenesis
of regional neurodegeneration. Comparison of CRX pro-
tein activity in transgenic and knockin models of SCA7
suggests that the diminished CRX protein activity found
in the transgenic model may be an artifact of abnormally
regulated expression of SCA7 mutant protein in the trans-
genic model (La Spada et al., 2001; Yoo et al., 2003).
Specific patterns of neurodegeneration may result from
neuron subpopulation-specific interactions between ex-
panded polyglutamine-containing protein fragments and
transcriptionally active proteins, and these specific pat-
terns of interaction may be distorted in transgenic models.
At least with respect to HD, however, the more aggressive
phenotypes exhibited by transgenic models are advanta-
geous for some purposes. Evaluating potential therapies is
easier in models with aggressive, early-onset phenotypes,
and it will be prohibitively expensive to evaluate all po-
tential therapies in HD knockin models. For all polyglu-
tamine disorders, a combination of results from both
transgenic and knockin models will likely be needed to
investigate pathogenesis and evaluate potential thera-
pies. Hprt(CAG)146 mice may be particularly useful in this
context. The wide expression of neuronal pathology in this
line allows study of polyglutamine toxicity in many brain
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regions with expression under the control of native ele-
ments.
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